BioSpace News Archive

T-Cypher Bio, a rapidly emerging private biotech company pioneering a novel approach to TCR therapeutics announces the appointment of Thomas Lars Andresen as Chief Executive Officer and member of the Board of Directors, effective from 1st August 2021.

Oxford Biomedica plc, a leading gene and cell therapy group, is pleased to announce that Dr. Michael Hayden has been appointed to the Group’s Board as a Non-Executive Director

Aravive Inc., a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, announced that it achieved a $3 million development milestone payment from its licensee, 3D Medicines Inc.

Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat genetically defined diseases, announced that the company will host a conference call and live webcast on Thursday, July 29, 2021 at 8:00 a.m. ET to report its second quarter 2021 financial results and other business highlights.

Adicet Bio, Inc., a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, announced the formation of a Scientific Advisory Board.

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced the appointment of Edgar Braendle M.D., Ph.D., as chief development officer.

Theratechnologies, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies, reported financial results for the second quarter ended May 31, 2021 and provided an update on its planned Phase 3 clinical trial evaluating tesamorelin for the treatment of nonalcoholic steatohepatitis.

Compugen Ltd. announced that the first patient has been dosed in its Phase 1 clinical study evaluating the dual combination of COM902, the Company’s potential best-in-class, high-affinity anti-TIGIT antibody and COM701, Compugen’s first-in-class anti-PVRIG antibody in patients with advanced malignancies who have exhausted all available standard therapies.

ZyVersa Therapeutics, Inc., a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, is pleased to announce that Stephen C. Glover, ZyVersa’s Co-Founder, Chief Executive Officer, and Chairman, is an invited speaker at the 2nd Annual LifeSci Partners’ Virtual Private Company Summer Symposium.

Lexaria Bioscience Corp., a global innovator in drug delivery platforms is pleased to announce results from its antiviral drug molecular characterization study VIRAL-MC21-1 recently completed by Canada’s premier federally funded research organization, the National Research Council.